Dendritic cell-derived exosomes (Dex) are nanoparticules (50-100 nm in diameter) originating from late endosomes. These vesicles are secreted by living dendritic cells (DCs) in the extracellular milieu and have demonstrated the capacity to activate innate and adaptive immunity. These immuno-stimulatory properties have stimulated researchers to use Dex as a cell free vaccine. The development of a production process following good laboratory practices has allowed the use of Dex in vaccination protocols in patients in the early 2000s. However, no modulation of adaptive immune responses was observed in these clinical trials. Thus the scientific community attempted to decipher mechanisms of action involved in the establishment of an effective immune response after Dex vaccination. The results stressed that the immunogenicity of Dex reflects the state of maturation of DCs. Taking into account these new knowledge, our team developed a new generation of Dex capable of inducing immune cellular responses against tumor antigens. Their effectiveness is currently being evaluated in patients suffering from non small cell lung cancer. Running title: Dendritic cell-derived exosomes as cell free vaccine
I) Dendritic cell-derived exosomes: from basic science to clinical trial
The interest for Dex began in 1998 when it was shown that these vesicles secreted into the culture supernatant of immature dendritic cells (immature Dex or "iDex") could induce stabilization and regression of tumors in mice. These antitumor effects induced by iDex pulsed with tumor antigens were dependant on CD8 + T cells in mice (Zitvogel et al., 1998) . Subsequently, it was demonstrated that iDex could activate CD4 + T cells by transferring MHC-II/antigen complexes to a recipient DC (Théry et al., 2002) and that human iDex could also transfer MHC-I/antigen complexes to a recipient DC for the polarization of Tc1 CD8 + T cells (André et al., 2004) . Thus, iDex do not activate T lymphocytes directly but need to be transferred on DCs. Studying different population of DCs that could be able to present Dex for the initiation of CD4 + T cell responses, CD8α -DCs were demonstrated to have the ability to present iDex's MHC-II/antigen complexes in vitro (Théry et al., 2002) . However, in vivo data suggested that endogenous CD8α + DCs were the main recipients of exosomes without the need for internalization and processing, LFA-1 being required for Dex capture (Segura et al., 2007) . Moreover, the necessity to administer an endogenous DCs' maturation agent (ie TLR-3 or -9) along with iDex, in vivo in mice, confirmed that Dex's MHC/antigen complexes required the intervention of an antigen-presenting cell to initiate a Tc1 immune response (Chaput et al., 2004) . Therefore, iDex promote the exchange of functional MHC/antigen complexes between DCs. Such a mechanism could increase the number of antigen presenting DCs thus amplifying the initiation of adaptive immune responses. These results provide a rational for the use of iDex as a therapeutic vaccine in patients bearing advanced cancer. After the development of a production method following good laboratory practices (Hsu et al., 2003; Lamparski et al., 2002) , two phase I clinical trials using autologous iDex pulsed with MAGE-3 peptides in patients with stage III/IV melanoma (French trial) and lung cancer (US trial) allowed us to monitor immunological responses. At this time iDex were injected without any adjuvant. These trials aimed at evaluating the feasibility of Dex production by autologous monocyte-derived DCs and the safety of Dex inoculation. Secondary endpoints were the immunomonitoring of peptide specific CD4 + and CD8 + T cell responses restricted by exosomal MHC class II and I molecules. Fifteen patients were included in the french trial and thirteen in the US trial. Feasibility and tolerance were good; however, no T cell responses were pointed out after iDex vaccinations (Escudier et al., 2005; Morse et al., 2005) . The discrepancy between some clinical responses and the lack of any detectable T cell responses (Tetramer stainings, Elispots) prompted the search for alternate effector mechanisms accounting for the tumoricidal activity. We studied NK activity in patients enrolled in these clinical trials and we could show that iDex were able to restore NK cell activity in half of treated patients Viaud et al., 2009 ). All of these preclinical and clinical studies have led to improve this vaccine approach in order to obtain Dex that could activate an effective adaptive immune response in vivo.
II) Strategies to improve Dex immunogenicity
Three strategies were explored to improve the antitumor efficacy of Dex: as already mentioned above the concomitant injection of an immunological adjuvant (TLR-3 or -9) (Chaput et al., 2004; Guo et al., 2008) , inhibition of CD4 (Taïeb et al., 2006) and finally the use of mature DC to produce Dex (mDEX) Qazi et al., 2009; Segura et al., 2005a , Segura et al., 2005b Sprent, 2005) . The role of Treg in restricting T cell based-immune responses has gained renewed recognition. Cyclophosphamide (CTX) at immunopotentiating doses has been shown to inhibit CD4 + CD25 + Treg cell activity (Ghiringhelli et al., 2004; Ghiringhelli et al., 2007) . Therefore, we investigated the combined effects of CTX and iDex to elicit antitumor immunity leading to tumor rejection in the poorly immunogenic B16F10 melanoma model in mice (Taïeb et al., 2006) . iDex-mediated anti-tumor effects were dramatically improved in CTX treated animals. CTX administrated 6 days before iDex vaccination was able to boost peptide specific secondary responses as assessed by immunomonitoring using specific fluorescent tetramers and IFNγ secretion by T cells after in vitro stimulation. Adoptive transfer of Treg curtailed CTX/iDex synergistic anti-tumor effects confirming the inhibiting role of Treg (Taïeb et al., 2006) . Modulation of Dex bioactivity through modulation of DCs maturation stage was first described by Robbins' team in 2005 (Kim et al., 2005 ). This first study shows that Dex derived from DC treated with IL-10 are tolerogenic, resulting in the suppression of inflammation and collagen-induced arthritis in mice (Kim et al., 2005; Ruffner et al., 2009 ). Thereafter, this team and others have shown that the treatment of DCs with indoleamine 2,3-dioxygenase (IDO) or IL-4 (Kim et al., 2007a) but also the loading of alloantigens on DCs (Montecalvo et al., 2008; Pêche et al., 2003; Pêche et al., 2006) could lead to the production of tolerating Dex. Some molecules have been identified as responsible for this tolerance: MHC-II complexes (Kim et al., 2007b) , Fas-L (Kim et al., 2006) , CD80 and CD86 ) (the two latter being weakly expressed on iDex). Conversely, it appears that exosomes secreted by mature DCs are immunogenic (mDex). Indeed, Dex produced from LPS-matured DC showed enrichment with ICAM-1 and CD86 leading to activation of CD4 + and CD8 + T cells (Segura et al., 2005b; Sprent, 2005) . These studies highlighted the fact that Dex can be tailor-made in vitro for the treatment of autoimmune diseases, viral infection as well as cancer. In our group, we have engineered human mDex, respecting good laboratory processes (GLP), harboring a phenotype with increased expression of MHC complexes and costimulation molecules suggesting potent adaptive immunity (unpublished data). These second generation mDex are currently tested in a phase II clinical trial in non small cell lung cancer (NSCLC) bearing patients (Viaud et al., 2010) . 
III) Molecules that regulate Dex immunogenicity (Fig. 1)
As mentioned above, modification of Dex molecular composition influences Dex's immune properties. Thus identification of molecules involved in immune responses generated by Dex seems paramount. Currently few molecules have been clearly identified. Some of them incline to immunogenicity: i) MHC molecules necessary to generate an adaptive immune response ii) CD54/ICAM-1 and mannose/glucosaminerich C-type lectin receptor ligands (Hao et al., 2007; Segura et al., 2007) that could favor the uptake by endogenous DCs iii) B7.2/CD86 and CD54/ICAM-1 that could induce CD4 + T cell responses (Segura et al., 2005b) or CD8 + T cell responses (Sprent, 2005) , iv) and B7.1/CD80 and B7.2/CD86 that could participate in DTH reactions ) and v) IL-15Rα and NKG2D-L that promote the activation and proliferation of NK cells (Viaud et al., 2009 ). Other molecules, in contrast, promote tolerance: i) CD95 ligand/FASL probably in enhancing lymphocytes apoptosis (Kim et al., 2006) , ii) MFG-E8/lactadherin (milk fat globule EGF factor VIII) highly expressed on iDex but weakly expressed on mDex (Segura et al., 2005a) could play a pivotal role in the immunogenicity of Dex. Indeed MFG-E8 (MFG-E8 binds to apoptotic cells, activated platelets, and phosphatidylserineexpressing cells via the C-domains and anchors them to macrophage integrins via its RGD sequence in the EGF domain) is involved in phagocytosis and destruction of apoptotic cells by macrophages (Hanayama et al., 2002 ) and could play a major role in maintaining peripheral tolerance (Asano et al., 2004; Hanayama et al., 2004) . Thus highly MFG-E8-expressing exosomes could target dying cells and/or apoptotic bodies ensuring their clearance leading to a silent cell death for the immune system. Recently, some studies have suggested that iDex (enriched with MFG-E8) rescue septic animals via MFG-E8 thanks to a systemic inflammatory response decrease in sepsis by enhancing apoptotic cell clearance (Miksa et al., 2009; Miksa et al., 2006) . By cons, mDEX expressing strongly ICAM-1 and weakly MFG-E8 could be mainly targeted on endogenous DCs and therefore be immunogenic (Segura et al., 2005a; Segura et al., 2005b; Segura et al., 2007) . Besides these molecules that have been well studied during the development of an immune response induced by Dex, other mediators could participate. Some researchers have deliberately modified DCs to Natural nanoparticules against cancer: mature dendritic cell-derived exosomes Viaud S, et al. Atlas Genet Cytogenet Oncol Haematol. 2011; 15(2) make them express pro/anti-inflammatory cytokines leading to production of Dex with modified immune capacities (Dai et al., 2006) . Recently, it has been shown that Dex could contain bioactive cytokines. One work suggested an alternative model of IL-1β release that may involve the P2X7R-induced formation of multivesicular bodies which contain exosomes with entrapped IL-1β and other inflammasome components (Qu et al., 2007) . Moreover, C. Obregon and colleagues have demonstrated that Dex could represent important carriers of TNF-α (Obregon et al., 2009 ) highlighting the key role of DC-derived exovesicles, not only in adaptive immunity, but also in innate immunity by triggering innate immune responses and activating neighboring epithelial cells to release cytokines and chemokines, thereby amplifying the magnitude of the innate immune response. Finally, immunoregulation of Dex could also be controlled by their microRNAs content. Indeed, DC maturation signals lead to the induction or reduction of microRNAs' pool, some of them being pro-inflammatory while others antiinflammatory (Lu and Liston, 2009; Rodriguez et al., 2007) . Given that exosomes contain microRNAs that can be transferred to a target cell (Valadi et al., 2007) and knowing that secreted microRNAs could be mainly contained in exosomes (Kosaka et al., 2010) (exosomes being resistant to complement attack (Clayton et al., 2003) and protected from RNAses (Valadi et al., 2007) ), it is conceivable that the microRNAs composition could influence the pro-or antiinflammatory properties of Dex; however this hypothesis remains to be confirmed.
IV) Conclusion and perspectives
Although the full understanding of the significance of Dex requires additional studies, these vesicles proved to be a naturally occurring minimal antigen presenting unit that could orchestrate immune responses according to various signals received by producing DCs (Théry et al., 2009) . Exosomes are secreted in large quantities by DCs in the absence of any stimulation (steady state), in this context exosomes might play a role mainly in tissue homeostasis in promoting apoptotic body clearance and avoiding harmful inflammation that could lead to autoimmune diseases development. By cons, in an antiinflammatory (IL-10, TGFβ, IDO ...) or a proinflammatory (LPS, Poly IC, IFNγ, ATP...) context, the molecular composition of Dex could play a fundamental role in shaping immune responses. Indeed, in vivo the targeting to one or the other exosomes presenting cell (MFG-E8, ICAM-1 ...), the expression of molecules that can regulate immunity (costimulatory molecules; FASL ...), the presence of inflammation mediators in Dex (IL-1β, TNFα, TGFβ1 ...) but also mRNAs or microRNAs content should dictate in vivo bioactivity of Dex. The role of Rab27a and Rab27b in regulating the secretion of exosomes has recently been identified (Ostrowski et al., 2010) ; this should enable us to build tools for the understanding of exosomes' role in different pathophysiological contexts. Our growing knowledge of the effects of Dex on immune responses and their potential use as therapeutic agents led us to develop second generation mDex in order to propose a maintenance immunotherapy in patients with advanced cancer (Fig. 2) (Viaud et al., 2010) . During this phase II clinical trial, we will have a unique opportunity to analyze the immunostimulatory capacity of mDex in a dynamic study in patients, to investigate their protein and nucleic acid content and to correlate those parameters with a potential and expected clinical efficacy in patients. Together, these studies should allow us to identify molecules essential for the bioactivity of mDex in vivo in cancer patients. + patients suffering from inoperable NSCLC (Stage IIIB / IV) and responders to induction chemotherapy, will receive Dex-based maintenance immunotherapy (oral low dose cyclophosphamide for 3 weeks followed by intradermal vaccinations with mDex pulsed with tumor antigens). Clinical response evaluation after 4 and 6 vaccines will allow determining the efficacy of this therapeutic approach. In addition, numerous samples (blood and tumor) will allow building a link between mDex immunogenicity and possible clinical responses.
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